NDAINHALATIONSPRAY, METERED
Approved
Jul 2014
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
3/8 — Basic
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STRIVERDI RESPIMAT is an inhaled metered-dose spray containing olodaterol, a long-acting beta-2 agonist (LABA) developed by Boehringer Ingelheim. It is indicated for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). The drug works by stimulating beta-2 adrenergic receptors in the airways, causing bronchodilation and improved airflow.
$5.0MPart D
LOE Approaching9mo to LOEWith LOE approaching in early 2027 and modest Part D spending of $5M, the brand team is likely in maintenance/transition mode with reduced headcount and budget allocation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Worked on STRIVERDI RESPIMAT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.